- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Orexo AB (ORX)
Orexo AB stock price live, this page displays ST ORX stock exchange data. View the ORX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Orexo AB real time stock price chart below.
What Is the Orexo AB Stock Price Today?
The Orexo AB stock price today is 20.2.
What Is the Stock Symbol for Orexo AB?
The stock ticker symbol for Orexo AB is ORX.
Is ORX the Same as $ORX?
$ORX is a common way to refer to the Orexo AB ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Orexo AB Trade On?
Orexo AB is listed and trades on the Stockholm stock exchange.
Is Orexo AB a Good Stock to Buy?
Determining whether Orexo AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Orexo AB share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ORX quote. (ISIN: SE0000736415)
What Is the Orexo AB Stock Price Today?
The Orexo AB stock price today is 20.2.
What Is the Stock Symbol for Orexo AB?
The stock ticker symbol for Orexo AB is ORX.
Is ORX the Same as $ORX?
$ORX is a common way to refer to the Orexo AB ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Orexo AB Trade On?
Orexo AB is listed and trades on the Stockholm stock exchange.
Is Orexo AB a Good Stock to Buy?
Determining whether Orexo AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Orexo AB share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ORX quote. (ISIN: SE0000736415)
Currency in SEK
20.2
+0.2(+1.00%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
19.7
20.3
52 wk Range
13.6
43.4
Earnings results expected tomorrow
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
19.720.3
52 wk Range
13.643.4
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ORX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori. The company is developing Izipry for opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; OX390 for overdoses caused by a combination of life-threatening illicit drugs; OX125 for opioid overdose with powder-based nalmefene; OX472 for intranasal formulation of semaglutide, a GLP-1 receptor agonist, developed using proprietary AmorphOX technology; and develops thermostable and needle-free mucosal vaccines. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
Orexo AB Earnings Call Summary for Q3/2025
- Q3 revenue of 119M SEK missed forecast, causing 14.8% stock drop. EBITDA negative at -9.8M SEK.
- OX390 received BARDA grant, supporting development until 2027. Company explores partnerships for GLP-1 and nasal delivery tech.
- Maintained 2025 EBITDA guidance despite challenges. Zubsolv revenue at 114M SEK, 96% of total.
- Advancing nasal delivery technology for semaglutide and other products. CEO touts 'world's leading nasal powder delivery'.
- Cash and equivalents at 106M SEK. Company valued at $115.65M with 87.23% gross profit margins.
Last Updated: 10/23/2025, 10:24 AM
Read Full TranscriptOrexo AB investor slides for Q3/2025
Last Update: Oct 23, 2025
See full investor slides
Compare ORX to Peers and Sector
Metrics to compare | ORX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipORXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.7x | 22.9x | −0.4x | |
PEG Ratio | 0.00 | 1.89 | 0.00 | |
Price / Book | 1.4x | 4.2x | 2.6x | |
Price / LTM Sales | 27.1x | 3.8x | 3.1x | |
Upside (Analyst Target) | 88.1% | 55.9% | 47.4% | |
Fair Value Upside | Unlock | 18.8% | 7.0% | Unlock |
Earnings
Latest Release
Feb 05, 2026
EPS / Forecast
-3.33 / -0.30
Revenue / Forecast
3.3M / 128.9M
FAQ
What Is the Orexo AB (ORX) Stock Price Today?
The Orexo AB stock price today is 20.2 SEK.
What Stock Exchange Does Orexo AB Trade On?
Orexo AB is listed and trades on the Stockholm Stock Exchange.
What Is the Stock Symbol for Orexo AB?
The stock symbol for Orexo AB is "ORX."
What Is the Orexo AB Market Cap?
As of today, Orexo AB market cap is 705.42M SEK.
What Is Orexo AB's Earnings Per Share (TTM)?
The Orexo AB EPS (TTM) is -11.7.
When Is the Next Orexo AB Earnings Date?
Orexo AB will release its next earnings report on Apr 28, 2026.
From a Technical Analysis Perspective, Is ORX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Orexo AB Stock Split?
Orexo AB has split 2 times.
How Many Employees Does Orexo AB Have?
Orexo AB has 74 employees.
What is the current trading status of Orexo AB (ORX)?
As of Apr 27, 2026, Orexo AB (ORX) is trading at a price of 20.2 SEK, with a previous close of 20.0 SEK. The stock has fluctuated within a day range of 19.7 SEK to 20.3 SEK, while its 52-week range spans from 13.6 SEK to 43.4 SEK.
What Is Orexo AB (ORX) Price Target According to Analysts?
The average 12-month price target for Orexo AB is 38.0 SEK, with a high estimate of 38 SEK and a low estimate of 38 SEK. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +88.12% Upside potential.
Industry Spotlight
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.